SM
LIPO

Sabby Management’s Lipella Pharmaceuticals LIPO Stock Holding History

Sabby Management’s Portfolio LIPO Stock Details LIPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-67,531
Closed -$243K – 55
2024
Q2 		$243K Buy
67,531
+36,294
+116% +$198K 0.16% 17
2024
Q1 		$171K Sell
31,237
-2,492
-7% -$18.5K 0.1% 26
2023
Q4 		$275K Buy
+33,729
New +$314K 0.28% 19

Other funds holding LIPO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sabby Management's LIPO Position: Q3 2024 in Review

Sabby Management sold out of Lipella Pharmaceuticals (LIPO) in Q3 2024, closing a stake of 67,531 shares — an estimated $243K sold.

Sabby Management first reported a position in LIPO in Q4 2023 and held it in 3 quarters. The position peaked at $275K in Q4 2023. 5 funds tracked by Wall St. Rank hold LIPO as of Q3 2024.

  • Sabby Management reported no remaining Lipella Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Sabby Management sold 67,531 Lipella Pharmaceuticals shares in Q3 2024, an estimated $243K.
  • Sabby Management first reported a position in Lipella Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Sabby Management's Lipella Pharmaceuticals position peaked at $275K in Q4 2023.
  • 5 funds tracked by Wall St. Rank held Lipella Pharmaceuticals as of Q3 2024.

Based on Sabby Management's 13F filing for Q3 2024, filed 14 Nov 2024.